The Latest Breaking News from Moderna

Vaccines are one of the greatest public health success stories of all time. Over the past 50 years, they’ve saved an estimated 154 million lives. But in the US, both access to vaccines and public trust in them are being systematically undermined – not by conspiracy theorists online, but from…

The avian flu virus is now just one mutation away from easier transmission among humans. Trump’s health chief is a grave risk to world health, says Prof Devi Sridhar, chair of global public health at the University of Edinburgh

‘A tremendous step backward, the politicization of science, and RFK Jr., who has been a lifelong anti-vaccine propagandist and science denialist, is now making policy,’ one doctor said

Scientists fear decision may increase vaccine hesitancy, but other countries are still willing to invest in research

As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Shares of Novavax Inc (NASDAQ:NVAX) are trading lower Friday morning, appearing to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna Inc (NASDAQ:MRNA) reported disappointing second-quarter financial results and cut its full-year forecast.

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago.

Moderna fell after reporting a smaller-than-expected Q2 loss and topped revenue views but the biotech lowered full-year sales guidance.

Moderna Inc. (NASDAQ:MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty.